Recent Advances in Treating Endometrial and Cervical Cancers - Episode 4

The Role of dMMR in the Progression of Endometrial Cancer

, , , ,

David M. O’Malley, MD, details the definition of dMMR (mismatch repair deficiency), its prevalence in advanced endometrial cancer, and current treatment approaches for dMMR patients, with a focus on the potential for cure in recurrent/metastatic dMMR patients based on clinical trial data.

EP. 1: Diagnosing and Staging Patients With Endometrial Cancer
EP. 2: Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer
EP. 3: Shared Decision-Making in Advanced or Recurrent Endometrial Cancer
Now Viewing
EP. 4: The Role of dMMR in the Progression of Endometrial Cancer
EP. 5: Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial
EP. 6: The NRG-GY018 Trial: Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer
EP. 7: Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer
EP. 8: Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer
EP. 9: Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer
EP. 10: Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer
EP. 11: Staging and Biomarker Testing For Patients With Cervical Cancer
EP. 12: Recent Updates in NCCN Guidelines for the Treatment of Recurrent or Metastatic Cervical Cancer
EP. 13: Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
EP. 14: Ocular Toxicity Management Strategies for Patients With Cervical Cancer Receiving ADCs
EP. 15: Clinical Trials Evaluating Tisotumab Vedotin in Patients with Recurrent or Metastatic Cervical Cancer
EP. 16: Emerging Data on Anti-HER2 ADCs in Patients With Cervical Cancer
EP. 17: Future Directions in the Treatment of Recurrent or Metastatic Cervical Cancer